Angiotensin II - Chia Tai Tianqing Pharmaceutical
Latest Information Update: 23 Apr 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Angiotensins; Anti-infectives; Anti-inflammatories; Antihypotensives; Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
- Mechanism of Action Angiotensin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Shock
Most Recent Events
- 08 Apr 2024 Preclinical trials in Shock in China (IV) prior to April 2024
- 08 Apr 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase III trial for Shock in China (NCT06351150)